Lassa Virus Genetics

Klitting, Raphaëlle; Mehta, Samar B.; Oguzie, Judith; Oluniyi, Paul E.; Pauthner, Matthias; Siddle, Katherine J.; Andersen, Kristian G.; Happi, Christian; Sabeti, Pardis C.

doi:10.1007/82_2020_212

Cited by 4 publications

(3 citation statements)

References 251 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…и длинного L (~7,2 т.п.н.). Каждый из них имеет 2 разнонаправленные открытые рамки считывания: S-сегмент кодирует гены вирусного нуклеопротеина (белок NP с молекулярной массой (MW) 63 кДа) и его прекурсора (белок GPС, MW = 75 кДа), L-сегментгены РНК-зависимой РНК-полимеразы (L-белок, MW = 200 кДа) и цинк-связывающего матриксного протеина (Z-белок, MW = 11 кДа) [14]. Нуклеопротеин является основным структурным белком; он инкапсулирует цепи РНК, формируя рибонуклеопротеиновые комплексы.…”

Section: лихорадка лассаunclassified

“…В линию VII входит 1 штамм, обнаруженный в государстве Того, для которого вирус ранее не считался эндемичным [19]. Генетическая вариабельность внутри вида составляет в среднем 20% для L-сегмента и 15% для S-сегмента, а внутри одной линии -до 10% для всего генома [14]. Подобное разнообразие ставит перед разработчиками серьёзную задачу по созданию универсальной пан-Ласса вакцины, обладающей кросс-протекцией против разных штаммов вируса.…”

Section: характеристика возбудителя лихорадкиunclassified

See 1 more Smart Citation

Review of candidate vaccines for the prevention of Lassa fever

Popova

Zubkova

Ozharovskaia

et al. 2021

Problems of Virology

View full text Add to dashboard Cite

The Lassa virus one of the main etiological agent of hemorrhagic fevers in the world: according to WHO estimates, it affects 100,000 to 300,000 people annually, which results in up to 10,000 deaths [1]. Although expansion of Lassa fever caused by this pathogen is mostly limited to the West African countries: Sierra Leone, Liberia, Guinea and Nigeria, imported cases have been historically documented in Europe, the United States of America (USA), Canada, Japan, and Israel [2]. In 2017, WHO included the Lassa virus in the list of priority pathogens in need of accelerated research, development of vaccines, therapeutic agents and diagnostic tools regarding infections they cause [3]. This review describes main technological platforms used for the development of vaccines for the prevention of Lassa fever.

show abstract

Section: лихорадка лассаunclassified

Section: характеристика возбудителя лихорадкиunclassified

Review of candidate vaccines for the prevention of Lassa fever

Popova

Zubkova

Ozharovskaia

et al. 2021

Problems of Virology

View full text Add to dashboard Cite

show abstract

“…1 LASV is a bi-segmented ambisense RNA virus and encoding of four multifunctional proteins: the nucleoprotein (NP), the RNA-dependent RNA polymerase large, a matrix RING-finger Zinc-binding protein, and the glycoprotein complex (GP). 2 A rodent-borne pathogen, LASV is primarily transmitted from infected rodents to humans via inhalation or ingestion of rodent excreta, though human-human and nosocomial transmission accounts for approximately 20% of Lassa fever cases. 3 With no licensed therapeutics or vaccines currently available for Lassa fever, rodent exclusion and pest management programs are recommended for prevention of LASV infection.…”

Section: Introductionmentioning

confidence: 99%

Novel Tools for Lassa Virus Surveillance in Peri-domestic Rodents

Smither

Koninga²,

Kanneh³

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

Background Lassa fever (LF) is a rodent-borne disease endemic to West Africa. In the absence of licensed therapeutics or vaccines, rodent exclusion from living spaces remains the primary method of preventing LF. Zoonotic surveillance of Lassa virus (LASV), the etiologic agent of LF, can assess the burden of LASV in a region and guide public health measures against LF. Methods In this study, we adapted commercially available LASV human diagnostics to assess the prevalence of LASV in peri-domestic rodents in Eastern Sierra Leone. Small mammal trapping was conducted in Kenema district, Sierra Leone between November 2018-July 2019. LASV antigen was detected using a commercially available LASV NP antigen rapid diagnostic test. LASV IgG antibodies against LASV nucleoprotein (NP) and glycoprotein (GP) were tested by adapting a commercially available semi-quantitative enzyme linked immunosorbent assay (ELISA) for detection of mouse-related and rat-related species IgG. Findings Of the 373 tested specimens, 74 (20%) tested positive for LASV antigen. 40 (11%) specimens tested positive for LASV NP IgG, while an additional 12 (3%) specimens only tested positive for LASV GP IgG. Simultaneous antigen presence and IgG antibody presence was linked in Mastomys sp. specimens (p < 0.01), but not Rattus sp. specimens (p = 1). Despite the link between antigen presence and IgG antibody presence in Mastomys sp., the strength of antigen response did not correlate with the strength of IgG response to either GP IgG or NP IgG. Interpretation The tools developed in this study can aid in the generation of valuable public health data for rapid field assessment of LASV burden during outbreak investigations and general LASV surveillance. Funding Funding for this work was supported by the National Institute of Allergy and Infectious Diseases National Institute of Health, Department of Health and Human Services under the following grants: International Collaboration in Infectious Disease Research on Lassa fever and Ebola - ICIDR - U19 AI115589, Consortium for Viral Systems Biology - CViSB - 5U19AI135995, West African Emerging Infectious Disease Research Center - WARN-ID - U01AI151812, West African Center for Emerging Infectious Diseases: U01AI151801.

show abstract

Lassa Virus Structural Biology and Replication

Garry

2023

Current Topics in Microbiology and Immunology

View full text Add to dashboard Cite

Lassa Virus Genetics

Cited by 4 publications

References 251 publications

Review of candidate vaccines for the prevention of Lassa fever

Review of candidate vaccines for the prevention of Lassa fever

Novel Tools for Lassa Virus Surveillance in Peri-domestic Rodents

Lassa Virus Structural Biology and Replication

Contact Info

Product

Resources

About